Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 1—January 2022
Synopsis

Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India

Samir Joshi, Rahul Telang, Muralidhar Tambe, Rajesh HavaldarComments to Author , Manasi Sane, Afshan Shaikh, Cherry Roy, Kireet Yathati, Sanjaykumar Sonawale, Rupalee Borkar, Rahul Magar, Harshal Bhitkar, Satish Shitole, Leena Nakate, Jyoti Kudrimoti, and Vidya Mave
Author affiliations: Byramjee-Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India (S. Joshi, R. Telang, M. Tambe, R. Havaldar, A. Shaikh, C. Roy, K. Yathati, S. Sonawale, R. Borkar, R. Magar, H. Bhitkar, S. Shitole, L. Nakate, J. Kudrimoti); Byramjee-Jeejeebhoy Government Medical College—Johns Hopkins University Clinical Research Site, Pune (S. Joshi, M. Sane, V. Mave)

Main Article

Table 1

Clinical characteristics of patients experiencing intensive rhino-sino-orbital and cerebral mucormycosis after undergoing treatment for COVID-19, India

Characteristic No. case-patients, n = 178
Age
Age, y, median (range) 51 (42–60)
Age group
<18 1 (1)
18–45 52 (29)
45–65 103 (58)
>65
22 (12)
Sex
M 125 (70)
F
53 (30)
Underlying illness
Diabetes mellitus
Previously diagnosed 88 (49)
Newly diagnosed 44 (25)
Hypertension 48 (27)
Chronic kidney disease 5 (3)
Cardiomyopathy 4 (2)
Asthma 2 (1)
HIV
1 (1)
COVID-19 characteristics†
Moderate COVID-19 122 (77)
Mild COVID-19 29 (18)
Severe COVID-19 8 (5)
Hospitalization, d, median (IQR) 10 (8–15)
Required oxygenation 103 (69)
Required ventilator support 5 (4)
Received intravenous steroids 82 (67)
Received oral steroids 12 (17)
Received antimicrobial drugs
95 (98)
Symptoms of mucormycosis
Facial pain 132 (74)
Headache 96 (54)
Nasal congestion 79 (44)
Nasal discharge 57 (32)
Vision impairment 66 (37)
Time from COVID-19 diagnosis to mucormycosis symptom onset, d (IQR)
28 (15–45)
Vital signs
Temperature, °F, median (IQR) 98 (98–98.6)
Heart rate >100 beats/min 4 (2)
Heart rate, beats/min, median (IQR) 88 (86–90)
Respiratory rate >20 breaths/min 29 (16)
Respiratory rate, breaths/min, median (IQR) 16 (12–18)
Median BP, systolic, mm Hg 123 (120–128)
Median BP, diastolic, mm Hg 80 (80–86)

*Values are no. (%) patients except as indicated. BP, blood pressure; COVID-19, coronavirus disease; IQR, interquartile range. †These characteristics represent diagnosis and treatment provided for COVID-19 prior to mucormycosis events.

Main Article

Page created: September 24, 2021
Page updated: December 20, 2021
Page reviewed: December 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external